Abstract
Frailty has been linked to an increased risk of coronavirus disease 2019 (COVID-19)-associated mortality, but evidence has been inconclusive and limited to hospitalized older individuals. Using data from the UK Biobank, we assessed whether frailty and comorbidity predict COVID-19 mortality in the overall community population (n=437,555) and in a selected COVID-19 positive sample (n=2,059). Frailty was assessed using the Rockwood Frailty Index (FI) and the Hospital Frailty Risk Score (HFRS), whereas comorbidity was assessed by the Charlson Comorbidity Index (CCI). Overall, 408 individuals died of COVID-19, as ascertained from the death register data. In the full sample, HFRS (odds ratio [OR] 1.07; 95% confidence interval [CI] 1.06–1.07) and CCI (OR 1.14; 95% CI 1.08–1.20) were associated with increased risk of COVID-19 mortality, while FI was not statistically significantly different from null in the multivariable logistic regression model. Adding HFRS or CCI to a model with only age and sex resulted in significantly larger areas under the receiver operating characteristic curves. Nevertheless, when restricting the analyses to COVID-19 positive cases, which is a sample with over-representation of frail individuals, neither of the frailty measures or CCI added meaningful predictive accuracy on top of age and sex. Besides, we observed stronger associations between HFRS categories and COVID-19 mortality in relatively younger (<75 years) than older individuals (≥75 years). Our results suggest that HFRS and CCI, which could be readily derived from medical records, may be useful for COVID-19 mortality risk stratification in the community.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was conducted using the UK Biobank resource, as part of the registered project 22224. This work was supported by the Swedish Research Council (2018-02077, 2019-01272), the Loo & Hans Osterman Foundation, the Strategic Research Program in Epidemiology at Karolinska Institutet and the Karolinska Institutet Foundations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study is covered by the general ethics review for the UK Biobank, conducted by North West Multi-Centre Research Ethics Committee (Reference: 16/NW/0274, 13 May 2016).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.